Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study.
about
Inflammatory Arthritis: A Newly Recognized Adverse Event of Immune Checkpoint BlockadeAnticytotoxic T-lymphocyte antigen-4 induced autoimmune hypophysitis: a case report and literature review.Radiographic Profiling of Immune-Related Adverse Events in Advanced Melanoma Patients Treated with Ipilimumab.Immune-mediated adverse events of anticytotoxic T lymphocyte-associated antigen 4 antibody therapy in metastatic melanoma.Ipilimumab (Anti-Ctla-4 Mab) in the treatment of metastatic melanoma: Effectiveness and toxicity management.Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor TherapyImmunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights.Risk of endocrine complications in cancer patients treated with immune check point inhibitors: a meta-analysis.Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review.Immune-Related Adverse Events From Immune Checkpoint Inhibitors.Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma.Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathiesRisk of endocrine adverse events in cancer patients treated with PD-1 inhibitors: a systematic review and meta-analysis.Immune checkpoint inhibitors: Navigating a new paradigm of treatment toxicities.Endocrine toxicity of immune checkpoint inhibitors: essential crosstalk between endocrinologists and oncologists.Isolated Adrenocorticotropic Hormone Deficiency Caused by Nivolumab in a Patient with Metastatic Lung Cancer.Corticosteroids and immune checkpoint blockade.Hypophysitis Secondary to Cytotoxic T-Lymphocyte-Associated Protein 4 Blockade: Insights into Pathogenesis from an Autopsy Series.Characterization of Thyroid Disorders in Patients Receiving Immune Checkpoint Inhibition Therapy.Pituitary Antibodies in an Adolescent with Secondary Adrenal Insufficiency and Turner Syndrome.Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma.Endocrine dysfunction induced by immune checkpoint inhibitors: Practical recommendations for diagnosis and clinical management.Adverse Renal Effects of Novel Molecular Oncologic Targeted Therapies: A Narrative Review.Two Cases of Atezolizumab-Induced Hypophysitis.Prevalence of hypophysitis in a cohort of patients with metastatic melanoma and prostate cancer treated with ipilimumab.Immune-related endocrine disorders in novel Immune checkpoint inhibition therapy.Management of gastrointestinal adverse events induced by immune-checkpoint inhibitors.SOCIETY FOR ENDOCRINOLOGY ENDOCRINE EMERGENCY GUIDANCE: Acute management of the endocrine complications of checkpoint inhibitor therapy.Targeting immune checkpoints in melanoma: an updateThe Current Understanding of the Endocrine Effects From Immune Checkpoint Inhibitors and Recommendations for Management
P2860
Q33793552-3CF8B564-3464-478E-A2EF-AC65F1531274Q35074088-4937CBA6-65E4-4A31-8BFC-6311F015FCE0Q36132702-925D3346-2823-4196-A999-D2E20E7E5B4BQ36173638-0DB2B91A-73FF-4EB9-91B2-E9541AF7DAD2Q37131014-421CA02D-E051-4BD9-91B4-DCE1F3EEDE18Q37629874-00090554-3C74-42E2-B6DB-E828DE3371C2Q38549542-5B7B891A-5292-4CE2-8E5D-BE82E8E3E6FCQ38699309-6575132C-FAA6-4ACA-BE24-23C55F89044FQ38783026-7B2B4258-4F1A-4968-A50E-216F81F72008Q38832640-44854D1A-74D9-4B01-B4E9-1E7AB5F12066Q38884560-2E82BA8A-BEC9-450F-B4DE-E9F694DC8626Q39010566-07BFB6DE-1616-49C5-A77F-EEB95A3A6A9CQ39148284-C192A625-3632-40EC-87E2-CFF8D36FD538Q39430042-F7DDF066-05BA-49BC-8116-E2E4444AC32AQ39441719-EBB789B9-B1B2-4707-A3D2-80E55ED0DAA6Q42378748-C216F41B-E0C7-4E07-A7BF-FDF49BEC43C2Q43237759-B84FF98F-3030-455C-8F5B-59679E18830CQ45839919-21550988-9EA1-45B2-B9B2-200A79CC62C8Q47106542-814D1978-92C8-46EA-8687-038009686A6FQ47141466-301197BD-FE73-4735-9AFA-24867886FEBEQ47906372-17DF9B69-97F5-439D-B80E-5AFB103A9322Q48289680-C2C3E5D9-4C3B-4D19-A1B3-040C9DAF39A1Q49188770-4A381AA3-B419-4FB3-AAD8-16D14034A64FQ52735144-F0A465F3-9239-4E64-A48C-FCD108508AD5Q52777255-205B0924-FDB0-4112-BA7A-3CB080FB1835Q53656848-CAE7A965-9F19-40F1-B6EA-D7F815B8CE5DQ55314300-970318A7-4D69-4755-99DA-063712C8D8A5Q55378086-C044949C-155B-4CDF-AE8A-A32F35DBA24BQ56895678-E72E117B-C1D3-4117-A693-A21BD93164D5Q57178624-B3E55E0C-F675-492B-A851-ECCD6F467BFC
P2860
Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study.
description
2014 nî lūn-bûn
@nan
2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Systemic high-dose corticoster ...... a retrospective cohort study.
@ast
Systemic high-dose corticoster ...... a retrospective cohort study.
@en
type
label
Systemic high-dose corticoster ...... a retrospective cohort study.
@ast
Systemic high-dose corticoster ...... a retrospective cohort study.
@en
prefLabel
Systemic high-dose corticoster ...... a retrospective cohort study.
@ast
Systemic high-dose corticoster ...... a retrospective cohort study.
@en
P2093
P2860
P1476
Systemic high-dose corticoster ...... a retrospective cohort study.
@en
P2093
Anita Giobbie-Hurder
Frank Stephen Hodi
Hilary Donahue
Jason J Luke
Meredith Davis
Patrick A Ott
Rona S Carroll
Ursula B Kaiser
P2860
P304
P356
10.1158/1078-0432.CCR-14-2353
P407
P577
2014-12-23T00:00:00Z